Monitorering af tumornekrosefaktor alfa-haemmeres biotilgaengelighed, farmakokinetik og immunogenicitet

Casper Steenholdt; Mark Ainsworth; Ole Østergaard Thomsen; Jørn Brynskov; Klaus Bendtzen

Monitorering af tumornekrosefaktor alfa-haemmeres biotilgaengelighed, farmakokinetik og immunogenicitet

Translated title of the contribution: [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors]

Casper Steenholdt
, Mark Ainsworth
, Ole Østergaard Thomsen
, Jørn Brynskov
, Klaus Bendtzen

Department of Gastroenterology

2 Citations (Scopus)

Abstract

Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.

Translated title of the contribution	[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	172
Issue number	1
Pages (from-to)	44-7
Number of pages	4
Publication status	Published - 4 Jan 2010

Cite this

@article{343f0caf6aeb4cb09ce9dd5b3d773a12,

title = "Monitorering af tumornekrosefaktor alfa-haemmeres biotilgaengelighed, farmakokinetik og immunogenicitet",

abstract = "Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.",

author = "Casper Steenholdt and Mark Ainsworth and Thomsen, \{Ole {\O}stergaard\} and J{\o}rn Brynskov and Klaus Bendtzen",

year = "2010",

month = jan,

day = "4",

language = "Dansk",

volume = "172",

pages = "44--7",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske L{\ae}geforening",

number = "1",

}

TY - JOUR

T1 - Monitorering af tumornekrosefaktor alfa-haemmeres biotilgaengelighed, farmakokinetik og immunogenicitet

AU - Steenholdt, Casper

AU - Ainsworth, Mark

AU - Thomsen, Ole Østergaard

AU - Brynskov, Jørn

AU - Bendtzen, Klaus

PY - 2010/1/4

Y1 - 2010/1/4

N2 - Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.

AB - Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.

M3 - Tidsskriftartikel

C2 - 20056095

SN - 1399-4174

VL - 172

SP - 44

EP - 47

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 1

ER -

Monitorering af tumornekrosefaktor alfa-haemmeres biotilgaengelighed, farmakokinetik og immunogenicitet

Abstract

Fingerprint

Cite this